Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
What is the ticker symbol for Galecto Inc? What does GLTO stand for in stocks?
GLTO is the stock ticker symbol of Galecto Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Galecto Inc (GLTO)?
As of Fri Dec 20 2024, market cap of Galecto Inc is 6.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of GLTO stock?
You can check GLTO's fair value in chart for subscribers.
Is Galecto Inc a good stock to buy?
The fair value guage provides a quick view whether GLTO is over valued or under valued. Whether Galecto Inc is cheap or expensive depends on the assumptions which impact Galecto Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLTO.